REL-1017
REL-1017-310
Phase 3 small_molecule completed
Quick answer
REL-1017 for Major Depressive Disorder is a Phase 3 program (small_molecule) at RELMADA THERAPEUTICS, INC. with 3 ClinicalTrials.gov record(s).
Program details
- Company
- RELMADA THERAPEUTICS, INC.
- Indication
- Major Depressive Disorder
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed